| Oxidative phosphorylation |
1.80 |
1.22e-1 |
93/133 (69.92%) |
ATP5ME;NDUFA4;PPA2;...
|
| Retrograde endocannabinoid signaling |
1.68 |
1.87e-1 |
118/148 (79.73%) |
GNG11;GRIA2;SLC17A6;...
|
| Glycosylphosphatidylinositol (GPI)-anchor biosynthesis |
1.62 |
2.89e-1 |
20/26 (76.92%) |
PIGN;PIGG;PIGF;...
|
| Oocyte meiosis |
1.60 |
2.74e-1 |
90/129 (69.77%) |
CCNB2;RBX1;ADCY1;...
|
| Cardiac muscle contraction |
1.59 |
2.24e-1 |
64/87 (73.56%) |
TPM1;CACNA2D2;CACNG3;...
|
| Thermogenesis |
1.59 |
1.88e-1 |
173/232 (74.57%) |
COA3;NDUFAF4;ACSL5;...
|
| N-Glycan biosynthesis |
1.58 |
1.79e-1 |
38/50 (76%) |
ALG6;MAN2A1;MAN1A2;...
|
| Pyrimidine metabolism |
1.56 |
2.01e-1 |
40/56 (71.43%) |
DCK;CDA;RRM2;...
|
| Glycosaminoglycan degradation |
1.56 |
1.79e-1 |
19/19 (100%) |
HGSNAT;HYAL2;HPSE;...
|
| Nicotine addiction |
1.55 |
1.64e-1 |
32/40 (80%) |
GRIA2;SLC17A6;GABRA1;...
|
| DNA replication |
1.55 |
1.59e-1 |
34/36 (94.44%) |
MCM6;POLE2;RFC2;...
|
| Huntington disease |
1.54 |
1.56e-1 |
233/306 (76.14%) |
GRIA2;AP2S1;PLCB1;...
|
| Non-alcoholic fatty liver disease |
1.53 |
1.50e-1 |
126/155 (81.29%) |
LEPR;CASP7;CYCS;...
|
| Mannose type O-glycan biosynthesis |
1.47 |
2.42e-1 |
14/23 (60.87%) |
RXYLT1;FUT9;B4GALT3;...
|
| Fanconi anemia pathway |
1.46 |
2.44e-1 |
36/54 (66.67%) |
REV1;RAD51C;ATR;...
|
| Folate biosynthesis |
1.46 |
2.35e-1 |
23/26 (88.46%) |
PTS;AKR1B10;MOCS2;...
|
| Cell cycle |
1.45 |
2.29e-1 |
110/124 (88.71%) |
CDKN2C;CCNB2;MCM6;...
|
| Parkinson disease |
1.45 |
2.32e-1 |
176/249 (70.68%) |
SNCA;GPR37;CYCS;...
|
| Amyotrophic lateral sclerosis |
1.44 |
2.36e-1 |
267/364 (73.35%) |
GRIA2;NEFH;CYCS;...
|
| Various types of N-glycan biosynthesis |
1.43 |
2.41e-1 |
26/39 (66.67%) |
MAN2A1;MAN1A2;MGAT4A;...
|
| Purine metabolism |
1.40 |
2.87e-1 |
102/129 (79.07%) |
DCK;RRM2;GUCY1A1;...
|
| GABAergic synapse |
1.37 |
3.29e-1 |
76/89 (85.39%) |
GNG11;GABBR1;SLC12A5;...
|
| Porphyrin and chlorophyll metabolism |
1.37 |
3.28e-1 |
23/43 (53.49%) |
HMBS;UGT2B28;BLVRB;...
|
| Melanogenesis |
1.36 |
3.33e-1 |
74/101 (73.27%) |
LEF1;EDNRB;WNT5A;...
|
| Morphine addiction |
1.36 |
3.25e-1 |
80/91 (87.91%) |
GNG11;PDE10A;PDE4A;...
|
| Pathways of neurodegeneration |
1.35 |
3.19e-1 |
354/475 (74.53%) |
WNT5A;GRIA2;FZD1;...
|
| Ubiquitin mediated proteolysis |
1.35 |
3.11e-1 |
87/140 (62.14%) |
HERC2;RBX1;CDC34;...
|
| Homologous recombination |
1.35 |
3.14e-1 |
35/41 (85.37%) |
RAD51C;RPA2;RAD54B;...
|
| Alzheimer disease |
1.34 |
3.31e-1 |
279/369 (75.61%) |
WNT5A;FZD1;SNCA;...
|
| Viral protein interaction with cytokine and cytokine re... |
1.33 |
3.39e-1 |
84/100 (84%) |
CXCL12;PPBP;CXCR2;...
|
| RNA degradation |
-1.36 |
3.45e-1 |
53/79 (67.09%) |
TENT4A;HSPA9;LSM5;...
|
| B cell receptor signaling pathway |
-1.36 |
3.56e-1 |
71/81 (87.65%) |
NFKBIE;INPP5D;JUN;...
|
| Glycine, serine and threonine metabolism |
-1.36 |
3.65e-1 |
31/40 (77.5%) |
SHMT2;ALAS1;DAO;...
|
| AGE-RAGE signaling pathway in diabetic complications |
-1.39 |
3.09e-1 |
97/100 (97%) |
COL4A1;IL1B;NFKB1;...
|
| Proteoglycans in cancer |
-1.39 |
3.12e-1 |
172/205 (83.9%) |
GRB2;PPP1CB;PAK1;...
|
| C-type lectin receptor signaling pathway |
-1.39 |
3.23e-1 |
93/104 (89.42%) |
CBLB;JUN;SYK;...
|
| PPAR signaling pathway |
-1.40 |
3.21e-1 |
66/74 (89.19%) |
RXRB;APOC3;ME3;...
|
| Protein processing in endoplasmic reticulum |
-1.40 |
3.32e-1 |
127/171 (74.27%) |
HSP90B1;CANX;MAP2K7;...
|
| Arginine and proline metabolism |
-1.41 |
3.04e-1 |
39/50 (78%) |
LAP3;PRODH2;PYCR1;...
|
| Synthesis and degradation of ketone bodies |
-1.41 |
3.13e-1 |
9/10 (90%) |
HMGCL;ACAT1;ACAT2;...
|
| Graft-versus-host disease |
-1.42 |
3.14e-1 |
32/42 (76.19%) |
IL1B;IL1A;HLA-F;...
|
| Herpes simplex virus 1 infection |
-1.42 |
3.30e-1 |
165/498 (33.13%) |
HLA-G;PTPN11;OAS3;...
|
| Mitophagy |
-1.44 |
3.00e-1 |
56/68 (82.35%) |
BNIP3L;UBC;CSNK2A1;...
|
| PI3K-Akt signaling pathway |
-1.46 |
2.69e-1 |
317/354 (89.55%) |
TCL1B;RBL2;COL6A2;...
|
| Terpenoid backbone biosynthesis |
-1.47 |
2.71e-1 |
18/22 (81.82%) |
PCYOX1;ACAT1;IDI1;...
|
| Viral carcinogenesis |
-1.49 |
2.42e-1 |
149/203 (73.4%) |
RANBP1;RB1;C3;...
|
| Melanoma |
-1.50 |
2.45e-1 |
68/72 (94.44%) |
PIK3CD;PDGFRA;BAX;...
|
| HIF-1 signaling pathway |
-1.50 |
2.60e-1 |
105/109 (96.33%) |
IGF1;PFKFB3;PDHA2;...
|
| Pentose phosphate pathway |
-1.51 |
2.71e-1 |
25/30 (83.33%) |
TKT;TKTL1;DERA;...
|
| Mineral absorption |
-1.58 |
1.50e-1 |
48/60 (80%) |
MT2A;SLC26A3;FTL;...
|
| ECM-receptor interaction |
-1.59 |
1.49e-1 |
80/88 (90.91%) |
CD47;COL4A1;LAMA5;...
|
| Starch and sucrose metabolism |
-1.60 |
1.54e-1 |
25/36 (69.44%) |
HK1;GPI;PYGB;...
|
| Glyoxylate and dicarboxylate metabolism |
-1.61 |
1.57e-1 |
23/30 (76.67%) |
SHMT2;CS;ACAT1;...
|
| Autoimmune thyroid disease |
-1.63 |
1.57e-1 |
46/53 (86.79%) |
TSHR;HLA-F;HLA-C;...
|
| Glycolysis / Gluconeogenesis |
-1.63 |
1.68e-1 |
56/67 (83.58%) |
PDHA2;AKR1A1;ALDOB;...
|
| alpha-Linolenic acid metabolism |
-1.66 |
1.39e-1 |
17/25 (68%) |
PLA2G2A;PLAAT3;FADS2
|
| Phagosome |
-1.68 |
1.37e-1 |
118/152 (77.63%) |
ITGB1;MPO;CORO1A;...
|
| Tyrosine metabolism |
-1.68 |
1.79e-1 |
30/36 (83.33%) |
HPD;DDC;PNMT;...
|
| Focal adhesion |
-1.73 |
1.54e-1 |
180/201 (89.55%) |
COL4A1;LAMA5;GRB2;...
|
| Steroid biosynthesis |
-1.75 |
2.40e-1 |
19/20 (95%) |
HSD17B7;MSMO1;CYP51A1;...
|
